ALEMBIC-LACOSAMIDE TABLET

국가: 캐나다

언어: 영어

출처: Health Canada

유효 성분:

LACOSAMIDE

제공처:

ALEMBIC PHARMACEUTICALS LIMITED

ATC 코드:

N03AX18

INN (국제 이름):

LACOSAMIDE

복용량:

50MG

약제 형태:

TABLET

구성:

LACOSAMIDE 50MG

관리 경로:

ORAL

패키지 단위:

60

처방전 유형:

Prescription

치료 영역:

MISCELLANEOUS ANTICONVULSANTS

제품 요약:

Active ingredient group (AIG) number: 0152810001; AHFS:

승인 상태:

APPROVED

승인 날짜:

2018-10-01

제품 특성 요약

______________________________________________________________________________
_Alembic-Lacosamide Product Monograph_
_ Page 1 of 43_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
ALEMBIC-LACOSAMIDE
Lacosamide Tablets
Tablets; 50 mg, 100 mg, 150 mg and 200 mg, Oral
Ph.Eur.
Antiepileptic Agent
ATC Code: N03AX18
Manufactured by:
Date of Initial Authorization:
Alembic Pharmaceuticals Limited
December 19, 2018
Alembic Road,
Vadodara – 390003,
Gujarat, India
Canadian Importer and Distributor:
Date of Revision:
Alembic Pharmaceuticals Canada Ltd.
February 7, 2023
2680, Matheson Blvd. East, Unit 102
Mississauga, Ontario
L4W 0A5, Canada
Submission Control Number: 271051
______________________________________________________________________________
_Alembic-Lacosamide Product Monograph_
_ Page 2 of 43_
RECENT MAJOR LABEL CHANGES
7 Warnings and Precautions, 7.1.1 Pregnant Women
02/2023
7 Warnings and Precautions, 7.1.2 Breast-feeding
02/2023
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL
CHANGES..............................................................................................2
TABLE OF CONTENTS
................................................................................................................2
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................................4
1.
INDICATIONS
................................................................................................................4
1.1 Pediatrics
................................................................................................................4
1.2
Geriatrics.................................................................................................................4
2.
CONTRAINDICATIONS
...................................................................................................4
4.
DOSAGE AND
ADMINISTRATION.....................................................................